AIT Therapeutics to Report Second Quarter Financial Results on Friday, August 11

REHOVOT, Israel and NEW YORK, July 27, 2017 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical stage anti-microbial therapeutic company treating respiratory diseases with nitric oxide (NO), will report financial results for the three- and six-months ended June 30, 2017 and host a conference call and webcast at 10:30am Eastern Time on Friday, August 11.

Conference Call & Webcast
Friday, August 11th @ 10:30am Eastern Time
Domestic: 877-874-1588
International: 719-325-2499
Passcode: 9831107
Replays available through August 25th: 
Domestic: 844-512-2921
International: 412-317-6671
Conference ID: 9831107

About AIT Therapeutics Inc. 
AIT Therapeutics Inc. is a clinical-stage anti-microbial therapeutic company developing novel non-antibiotic anti-microbial therapeutics for respiratory diseases based on nitric oxide (NO) as well as other indications.  The Company is applying its therapeutic expertise to prevent and treat lower respiratory tract infections, many of which cannot effectively be addressed with current standards of care.  AIT Therapeutics is advancing its revolutionary respiratory targeted system in a pipeline of clinical trials for the treatment of bronchiolitis (RSV) exacerbations, and nontuberculous mycobacteria (NTM).  For more information, visit

Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.

Bob Yedid
LifeSci Advisors, LLC
(646) 597 6989

Source: AIT Therapeutics, Inc.